Introduction
============

Malignant melanoma is the most aggressive malignant tumor in the skin, and there is a clear trend toward familial clustering.[@b1-ott-11-5303] Of all patients who die of skin tumors, approximately 80% have malignant melanoma.[@b2-ott-11-5303] In 2018, the number of new cases of malignant melanoma in the US was estimated to be 91,270, and the estimated death toll was 9,320.[@b3-ott-11-5303]

The cell cycle includes four consecutive phases, from the stationary phase (G0 phase) to the proliferative phases (G1 phase, S phase, G2 phase, and M phase) and back to the stationary phase.[@b4-ott-11-5303] The key to developing malignant cells is the destruction of normal cell cycle progression, especially in G1 phase. Subsequently, cell cycle-associated regulatory proteins and signal transduction pathways are altered to allow tumor cells to successfully undergo cell cycle progression, lose their ability to differentiate, and undergo malignant proliferation.[@b5-ott-11-5303]

The mechanistic mechanism of melanoma involves the abnormal expression of multiple genes associated with cell cycle. The most important of these genes are those that play an important role in normal cell cycle activity but are overexpressed in cancer, interfering with the cell cycle and promoting the development of tumors. For example, the *USP39* gene is highly expressed in melanoma. Silencing *USP39* can inhibit the proliferation of melanoma cells in vitro and in vivo, induce G0/G1 arrest, and promote apoptosis. The *STAT3* gene is highly expressed in melanoma, and *STAT3* promotes tumor cell growth by regulating the expression of genes involved in cell survival and proliferation.[@b6-ott-11-5303] The *cyclin E* gene is also highly expressed in melanoma. *Cyclin E* interacts with CDK2 to form the cyclin E-CDK2 complex, which is highly expressed in both local and metastatic melanoma.[@b7-ott-11-5303]

With the release of relevant cancer data in The Cancer Genome Atlas (TCGA) database, cancer-related research has advanced. In this study, we found in the catalog of cancer somatic mutations (TCGA database) that the *E2F3* gene ranked first with a 28.12% increase in expression in melanoma. However, few studies have examined the role of E2F3 in melanoma. We will explore the mechanisms that lead to elevated E2F3 in melanoma and evaluate its associated carcinogenic properties.

Methods
=======

Bioinformatics
--------------

The catalog of cancer somatic mutations[@b8-ott-11-5303] is the world's greatest source of manual mapping of somatic mutations related to human cancer and is used to assess methylation mutations in human cancer tissues. TCGA melanoma expression level data, copy number data, and methylation data were downloaded from the TCGA website (<https://cancergenome.nih.gov/>). The Oncomine website (<https://www.oncomine.org/resource/login.html>) provided E2F3 expression analysis in the TCGA and gene expression omnibus (GEO) (accession number GSE3189 and GSE7553) databases. In addition, we have provided two supplemental tables on the data used in this article. More details about the raw data can be found in [Tables S1](#SD1-ott-11-5303){ref-type="supplementary-material"} and [S2](#SD2-ott-11-5303){ref-type="supplementary-material"}.

Cell culture
------------

The human malignant melanoma cell lines SK-MEL-28, MuM-2C, A-375, and HaCaT were purchased from American Type Culture Collection, Manassas, VA, USA, and the cells were maintained according to the manufacturer's protocol. The cells were cultured with Dulbecco's Modified Eagle's Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum and antibiotics (100 µg/mL streptomycin and 100 U/mL penicillin). All cells were cultured in a humidified environment at 37°C and 5% CO~2~. The use of the cell lines was approved by the ethics board. of Xiangya Hospital of Central South University.

Lentiviral production and transduction
--------------------------------------

The shRNA targeting *E2F3* (5′-TTGCGTTACTTTAA GTACTAA-3′; shR-*E2F3*; Thermo Fisher Scientific) was designed, and the scramble sequence (5′-TTCTCCGAACG TGTCACGT-3′) was used as a lentivirus negative control (NC). The human malignant melanoma cell line A375 was transfected with *E2F3*-shRNA and NC-shRNA viruses. The transfection efficiency of the recombinant lentivirus was tested by fluorescence microscopy (Olympus Corporation, Tokyo, Japan), and RT-PCR was used to assess the efficiency of knockdown.

RNA purification and reverse transcription PCR
----------------------------------------------

Total RNA was extracted using TRIZOL reagent (Thermo Fisher Scientific). The reverse transcription reaction was performed using a ReverTra Ace qPCR RT Master Mix with a gDNA remover (Toyobo Co., Ltd., Osaka, Japan). The cDNA was amplified by the KODSYBR^®^ qPCR Mix (Toyobo Co., Ltd.) on a LightCycler^®^ 480II System (Hoffmann-La Roche, Basel, Switzerland) according to the manufacturer's instructions. The primer sequences for the target gene were as follows: forward primer 5′-TATCCCTAAACCCGCTTCC-3′, reverse primer 5′-TTCACAAACGGTCCTTCTA-3′.

DNA purification
----------------

DNA was isolated using the Easypure Genomic DNA Kit (TransGen Biotech, Beijing, People's Republic of China) according to the manufacturer's instructions. The concentration of DNA was assessed spectrophotometrically and confirmed by gel electrophoresis, and the DNA was stored at −20°C. The results were normalized to *glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* gene expression.

Analysis of DNA methylation
---------------------------

For bisulfite-polymerase chain reaction, the BSP primer was designed in MethPrimer 2.0.[@b9-ott-11-5303] Then, the bisulfate-modified DNA was amplified with forward and reverse primers for target genes (bisulfite sequencing or restriction PCR, BSP). The DNA fragments were purified using the Gene JET Gel Extraction Kit (Thermo Fisher Scientific) and mixed at the appropriate proportions. According to the kit instructions, the second-generation sequencing library was prepared with the VAHTSTM Turbo DNA Library Prep Kit (Vazyme Biotech Co., Ltd., Nanjing, China) for Illumina Kits (Illumina, Inc., San Diego, CA, USA), and sequencing was performed with the Illumina MiSeq high-throughput sequencing platform (Illumina, Inc.). The primers for the bisulfite sequencing were as follows: forward primer 5′-GGATYGTTTTAGGTTAGGGAGT-3′, reverse primer 5′-AAAARGAAAACAACTAAATTCC-3′.

Plate colony formation assay
----------------------------

Melanoma cells transfected with *E2F3*-shRNA lentivirus were used to prepare cell suspensions and counted. Two hundred cells were added to a six-well plate. The cells were further cultured in a cell incubator for 14 days, the cell culture medium was changed every 3 days, and the cell state was observed. Photographs were taken with a fluorescence microscope before the end of the experiment, and the cells were washed twice with PBS. Then, 500 µL of Giemsa dye was added to each well, and the cells were stained for 10--20 minutes. The cells were washed three times with ddH~2~O and photographed with a digital camera.

Anchorage-dependent growth
--------------------------

The cells were suspended in 0.3% agar medium (DMEM containing 10% FBS) and plated on a 0.6% agar matrix layer at a concentration of 3.0×10^4^ cells/60 mm dish. The cells were cultured in a humidified environment (5% CO~2~) at 37°C. The number of colonies that were 50 µm or larger were counted after 2 weeks.

EdU cell proliferation assay
----------------------------

Lentivirus-transfected melanoma cells in the logarithmic growth phase were seeded in 96-well plates. Then, 100 µL of 50 µmol/L EdU medium was added per well, and the plates were washed with PBS after 2 hours and fixed. Each well was sequentially supplemented with 100 µL of 1× Apollo staining reaction solution and 100 µL of 1× Hoechst 33,342 nuclear staining reaction solution, evaluated by EdU detection and photographed by inverted fluorescence microscopy.

Cell cycle analysis
-------------------

Melanoma cells transfected with *E2F3*-shRNA lentivirus were incubated in six-well plates. When the cells reached 80% confluence, the medium was removed, the cells were suspended, and the supernatant was discarded by centrifugation. The cell pellet was washed with cold PBS. Cells were collected by centrifugation and fixed in 75% cold ethanol for 1 hour. Prior to analysis, the cells were washed with PBS again and suspended in a solution containing 10 µg/mL RNase A and 50 µg/mL propidium iodide. The cell suspension was filtered at a rate of 300 cells/second, and the cell cycle was analyzed by a FACSCalibur^™^ flow cytometer (BD Biosciences, San Jose, CA, USA).

Statistical analysis
--------------------

GraphPad Prism 7 software was used to analyze the data. Methylation, copy number variation (CNV), and expression levels between normal and cancer tissues were assessed by a two-tailed unpaired Student's *t*-test, and the error bars in the figure represent the SD or SEM. Spearman's correlation coefficient (*r*) was used to determine the correlation. Receiver operator characteristic curves were constructed based on the level of *E2F3* gene expression. The data were considered significant at *P*\<0.05.

Results
=======

High expression of the *E2F*3 gene in melanoma
----------------------------------------------

Based on the TCGA data, we found that among the genes with high expression in melanoma, the *E2F3* gene ranked first with an increase of 28.12% ([Figure 1A and C](#f1-ott-11-5303){ref-type="fig"}). The *E2F3* gene may promote the development of melanoma. It is worth noting that E2F3-related research in the skin is extremely rare, while studies in the eye, lung, and breast are more common ([Figure 1B](#f1-ott-11-5303){ref-type="fig"}). We found that the lung and breast ranked second and third, respectively, while melanoma ranked first ([Figure 1C](#f1-ott-11-5303){ref-type="fig"}). Therefore, it is necessary to study the relationship between *E2F3* and melanoma. Further study found that *E2F3* gene expression was increased in the TCGA and GEO databases ([Figure 1D](#f1-ott-11-5303){ref-type="fig"}), and the ROC curve of GSE3189 revealed that *E2F3* can identify melanoma tissue (AUC=0.9709) ([Figure 1E](#f1-ott-11-5303){ref-type="fig"}). Survival analysis showed that high *E2F3* expression results in decreases in OS and disease-free survival (DFS) of patients ([Figure 1F and G](#f1-ott-11-5303){ref-type="fig"}).

The relationship between CNV and *E2F3* expression level
--------------------------------------------------------

We sought to explore the cause of the high expression of *E2F3*. First, we found that *E2F3* showed extensive copy number amplification (CNA) and high DNA expression in solid cancers ([Figure 2A](#f2-ott-11-5303){ref-type="fig"}), and amplification was the main cause of high gene expression. Therefore, we hypothesized that the high expression of *E2F3* in melanoma was caused by CNA. The TCGA database showed that the expression *E2F3* level significantly increased in tissues with high copy number compared with tissues with low copy number ([Figure 2B](#f2-ott-11-5303){ref-type="fig"}). The expression of the *E2F3* gene was significantly positively correlated with CNV level ([Figure 2C](#f2-ott-11-5303){ref-type="fig"}), showing that CNA is one of the causes of the increase in *E2F3*. More importantly, we found that CNV was significantly associated with clinical prognosis, with significantly lower OS and DFS in patients with high copy number ([Figure 2D and E](#f2-ott-11-5303){ref-type="fig"}).

The relationship between DNA methylation and *E2F3* gene expression in the promoter region
------------------------------------------------------------------------------------------

In addition to CNA, promoter methylation is another mechanism that controls expression levels that should not be overlooked. In investigating whether high *E2F3* expression is regulated by methylation, we found that *E2F3* expression in hypermethylated tissues was obviously lower than that in tissues with low methylation by analyzing the TCGA database ([Figure 3A](#f3-ott-11-5303){ref-type="fig"}), and the methylation level was significantly negatively correlated with the *E2F3* expression level ([Figure 3B](#f3-ott-11-5303){ref-type="fig"}). However, we showed that methylation level did not affect OS or DFS ([Figure 3C and D](#f3-ott-11-5303){ref-type="fig"}). The promoter region of *E2F3* was heavily enriched with CpG islands ([Figure 3E](#f3-ott-11-5303){ref-type="fig"}), further confirming this trend. The methylation status of 19 CpG sites in the promoter region in four cell lines was analyzed by bisulfite sequencing PCR. The results showed that the promoter region was hypom-ethylated in both normal cells and malignant tumor cells and that there was no correlation between methylation and expression levels ([Figure 3F--I](#f3-ott-11-5303){ref-type="fig"}; [Tables S3](#SD3-ott-11-5303){ref-type="supplementary-material"} and [S4](#SD4-ott-11-5303){ref-type="supplementary-material"}). These results suggest that methylation may not be the cause of the elevated *E2F3* expression.

Carcinogenic properties of the *E2F3* gene
------------------------------------------

Research about whether high *E2F3* expression can promote the progression of melanoma is still lacking. To solve this problem, we successfully knocked down the *E2F3* gene in melanoma cells. Melanoma cells that lacked the *E2F3* gene showed reduced proliferation in colony formation ([Figure 4A and B](#f4-ott-11-5303){ref-type="fig"}), anchorage-dependent growth ([Figure 4C and D](#f4-ott-11-5303){ref-type="fig"}), and EdU cell proliferation experiments ([Figure 4E and F](#f4-ott-11-5303){ref-type="fig"}). These experiments show that E2F3 can affect cell proliferation. At the same time, we found that the G0/G1 population increased significantly after *E2F3* gene knockdown ([Figure 4G and H](#f4-ott-11-5303){ref-type="fig"}), which indicates that *E2F3* regulates the cell cycle and promotes melanoma.

Discussion
==========

The *E2F3* gene is located on chromosome 6p22 and is 91.5 kb in length. E2F3 is a major member of the E2F family and plays an important role in regulating the cell cycle, proliferation, and apoptosis.[@b10-ott-11-5303]

Feber et al found *E2F3* gene amplification on chromosome 6p22 in the bladder cancer cell lines TCCSUP and HT1376. Analysis showed that higher clinical stage and pathological grade of bladder cancer corresponded with a higher positive rate of *E2F3* expression.[@b11-ott-11-5303] Silven Bilke et al found that approximately 2/3 of prostate cancers showed high expression of *E2F3*. *E2F3* can be used as an independent factor to predict the OS of prostate cancer patients through multivariate analysis.[@b12-ott-11-5303] Ren et al found that miR-449a inhibits the expression of *E2F3*, which decreased when miR-449a was overexpressed in the lung cancer cell lines A549 and 95D. Another study found cell cycle arrest in G1 phase and inhibition of cell proliferation.[@b13-ott-11-5303] Libertini et al found that the expression of *E2F3* in laryngeal squamous cell carcinoma was significantly higher than that in normal nasopharyngeal mucosa (*P*\<0.001), and less differentiation correlated with a higher expression level (*P*\<0.05).[@b14-ott-11-5303] However, it is worth noting that we found that the expression level of the *E2F3* gene was the highest in melanoma, ranking first among all tissues, but few studies have explored this relationship. Therefore, it is necessary to conduct in-depth studies. We also confirmed that E2F3 can interfere with the cell cycle to promote the development of melanoma.

Many studies have found that CNV is an important factor affecting the prognosis of cancer patients. Specific CNVs can be used to assess prognosis.[@b15-ott-11-5303] A meta-analysis showed that *MET* gene amplification is inversely related to the OS of non-small-cell lung cancer patients and increases the risk of death.[@b16-ott-11-5303] Liu et al reported that lung cancer patients with four copies of the *mitogen-activated protein kinase-activated protein kinase 2* (*MAPKAPK2*) gene promoter have a shorter median survival and a 47% increased risk of death compared to those with two or three copies, which shows that the *MAPKAPK2* gene can be used as a genetic marker to predict the prognosis of lung cancer.[@b17-ott-11-5303] We confirmed that E2F3 was also regulated by this mechanism.

In addition to CNV, promoter methylation has been shown to affect gene expression in numerous studies. For example, Kim et al found that hypomethylation of the *NAT1* gene may increase the transcriptional activation of breast cancer genes. Therefore, the hypomethylated *NAT1* gene plays an important role in the development of breast cancer.[@b18-ott-11-5303] Other related studies include those on FGFR (sarcoma),[@b19-ott-11-5303] PRAME (leukemia),[@b20-ott-11-5303] and IGF2 (colorectal cancer).[@b21-ott-11-5303] The promoter hypermethylation of these genes is closely related to the occurrence of the corresponding tumors. In our study, we found that the expression level of the *E2F3* gene was negatively correlated with methylation but did not affect the prognosis of patients. Moreover, there was no correlation between the methylation and expression levels in four cell lines. It can be inferred that methylation may be one of the reasons for the high expression of *E2F3*, but more research needs to be done.

In summary, we discussed the mechanism of the high expression of *E2F3* in melanoma. Finally, we knocked down the *E2F3* gene with lentivirus, which significantly reduced the proliferation of melanoma cells and increased the proportion of cells in the G0 phase. Therefore, it can be speculated that E2F3 can promote cancer. However, considering the extensive and high expression of *E2F3*, more in-depth research is needed.

Supplementary materials
=======================

###### 

GSE3189

  Samples    Name column   E2F3
  ---------- ------------- ----------
  GSM71671   Normal        215.25
  GSM71672   Normal        153.95
  GSM71673   Normal        265.3
  GSM71674   Normal        199.4
  GSM71675   Normal        327.95
  GSM71676   Normal        163.7
  GSM71677   Normal        203.3
  GSM71678   Nevus         319.5
  GSM71679   Nevus         283.85
  GSM71680   Nevus         369.7
  GSM71681   Nevus         225.4
  GSM71682   Nevus         199.2
  GSM71683   Nevus         270.55
  GSM71684   Nevus         295.1
  GSM71685   Nevus         304.3
  GSM71686   Nevus         326.3
  GSM71687   Nevus         290.7
  GSM71688   Nevus         306.95
  GSM71689   Nevus         372.55
  GSM71690   Nevus         184.05
  GSM71691   Nevus         365.15
  GSM71692   Nevus         369.8
  GSM71693   Nevus         294.65
  GSM71694   Nevus         367.75
  GSM71695   Nevus         642
  GSM71696   Melanoma      584.9
  GSM71697   Melanoma      669.35
  GSM71698   Melanoma      439.55
  GSM71699   Melanoma      493.05
  GSM71700   Melanoma      417.3
  GSM71701   Melanoma      549.8
  GSM71702   Melanoma      649.4
  GSM71703   Melanoma      558.9
  GSM71704   Melanoma      449.25
  GSM71705   Melanoma      689.95
  GSM71706   Melanoma      713.9
  GSM71707   Melanoma      786.1
  GSM71708   Melanoma      1,071.75
  GSM71709   Melanoma      405.55
  GSM71710   Melanoma      686.95
  GSM71711   Melanoma      634.85
  GSM71712   Melanoma      464.4
  GSM71713   Melanoma      624.65
  GSM71714   Melanoma      610.55
  GSM71715   Melanoma      676.65
  GSM71716   Melanoma      810.25
  GSM71717   Melanoma      659.05
  GSM71718   Melanoma      498.05
  GSM71719   Melanoma      604.75
  GSM71720   Melanoma      368.95
  GSM71721   Melanoma      526.55
  GSM71722   Melanoma      511.15
  GSM71723   Melanoma      582.1
  GSM71724   Melanoma      519.85
  GSM71725   Melanoma      740.1
  GSM71726   Melanoma      602.05
  GSM71727   Melanoma      399.4
  GSM71728   Melanoma      435.4
  GSM71729   Melanoma      423.1
  GSM71730   Melanoma      423
  GSM71731   Melanoma      557.65
  GSM71732   Melanoma      537.55
  GSM71733   Melanoma      536.95
  GSM71734   Melanoma      539.95
  GSM71735   Melanoma      733.9
  GSM71736   Melanoma      780.4
  GSM71737   Melanoma      999.3
  GSM71738   Melanoma      669.75
  GSM71739   Melanoma      563.9
  GSM71740   Melanoma      490.6

###### 

GSE7553

  Samples     Name column                          E2F3
  ----------- ------------------------------------ ------------
  GSM183222   Melanoma in situ                     596.8995
  GSM183223   Melanoma in situ                     485.8525
  GSM183226   Metastatic melanoma                  1,043.514
  GSM183227   Metastatic melanoma                  1,065.36
  GSM183228   Metastatic melanoma                  1,097.4305
  GSM183229   Metastatic melanoma                  1,367.071
  GSM183230   Metastatic melanoma                  904.909
  GSM183231   Metastatic melanoma                  966.979
  GSM183232   Metastatic melanoma                  795.534
  GSM183233   Metastatic melanoma                  1,049.4855
  GSM183252   Metastatic melanoma                  1,675.07
  GSM183253   Metastatic melanoma                  1,161.0115
  GSM183254   Metastatic melanoma                  676.6665
  GSM183255   Metastatic melanoma                  1,252.875
  GSM183256   Metastatic melanoma                  1,091.715
  GSM183257   Metastatic melanoma                  1,446.735
  GSM183273   Metastatic melanoma                  763.7105
  GSM183274   Metastatic melanoma                  1,067.1765
  GSM183275   Metastatic melanoma                  972.223
  GSM183276   Metastatic melanoma                  984.8085
  GSM183277   Metastatic melanoma                  935.2895
  GSM183278   Metastatic melanoma                  1,323.74
  GSM183279   Metastatic melanoma                  757.3935
  GSM183280   Metastatic melanoma                  1,052.9955
  GSM183281   Metastatic melanoma                  970.099
  GSM183282   Metastatic melanoma                  1,097.2135
  GSM183283   Metastatic melanoma                  1,349.745
  GSM183284   Metastatic melanoma                  973.492
  GSM183285   Metastatic melanoma                  959.895
  GSM183286   Metastatic melanoma                  967.631
  GSM183287   Metastatic melanoma                  1,336.92
  GSM183288   Metastatic melanoma                  918.0085
  GSM183289   Metastatic melanoma                  1,649.06
  GSM183290   Metastatic melanoma                  1,127.6965
  GSM183291   Metastatic melanoma                  1,256.515
  GSM183292   Metastatic melanoma                  1,410.8
  GSM183293   Metastatic melanoma                  1,364.66
  GSM183294   Metastatic melanoma                  3,495.27
  GSM183295   Metastatic melanoma                  921.3215
  GSM183296   Metastatic melanoma                  1,392.965
  GSM183297   Metastatic melanoma                  582.005
  GSM183298   Metastatic melanoma                  1,088.088
  GSM183299   Normal human epidermal melanocytes   821.5565
  GSM183234   Normal skin                          289.57
  GSM183300   Normal skin                          554.652
  GSM183301   Normal skin                          360.1345
  GSM183302   Normal skin                          359.8905
  GSM183224   Primary melanoma                     454.667
  GSM183225   Primary melanoma                     472.3105
  GSM183235   Primary melanoma                     2,032.71
  GSM183258   Primary melanoma                     3,043.785
  GSM183259   Primary melanoma                     1,404.6755
  GSM183260   Primary melanoma                     1,513.8725
  GSM183261   Primary melanoma                     1,540.7
  GSM183262   Primary melanoma                     797.319
  GSM183263   Primary melanoma                     1,008.3395
  GSM183264   Primary melanoma                     733.7925
  GSM183265   Primary melanoma                     1,466.6135
  GSM183266   Primary melanoma                     838.3575
  GSM183303   Primary melanoma                     1,035.0555
  GSM183304   Primary melanoma                     612.168

###### 

E2F3 gene relative expression of by PCR

  Cell name   GAPDH   E2F3    ΔCt
  ----------- ------- ------- ------
  SK-MEL-28   13.07   22.12   9.05
  12.8        22.11   9.31    
  12.93       22.15   9.22    
  MUM-2C      12.81   20.85   8.04
  12.76       20.97   8.21    
  12.47       20.91   8.44    
  A375        12.43   21.7    9.27
  12.23       21.75   9.52    
  12.16       21.91   9.75    
  HaCaT       13.35   20.99   7.64
  13.31       21.25   7.94    
  13.27       21.32   8.05    

###### 

E2F3 pair all sample site methylation information table

  E2F3 pair methylation position   SK-MEL-28   MUM-2C   A-375    HaCaT
  -------------------------------- ----------- -------- -------- --------
  23                               0.0031      0.0041   0.0041   0.0033
  26                               0.0039      0.0045   0.0037   0.0043
  65                               0.0038      0.003    0.0029   0.0039
  75                               0.0041      0.0036   0.0029   0.0049
  78                               0.0033      0.0045   0.0026   0.0038
  81                               0.0035      0.0039   0.0021   0.0039
  102                              0.0021      0.0027   0.0022   0.0039
  104                              0.0036      0.0043   0.0027   0.0024
  111                              0.0036      0.0038   0.0027   0.0038
  113                              0.003       0.0047   0.0035   0.0033
  117                              0.0033      0.0039   0.003    0.0039
  123                              0.0031      0.0024   0.0032   0.0039
  128                              0.0051      0.004    0.0036   0.0039
  134                              0.0021      0.0049   0.0025   0.0037
  137                              0.0035      0.0042   0.0039   0.0039
  144                              0.0045      0.0041   0.0042   0.0032
  166                              0.0051      0.0049   0.0033   0.0035
  169                              0.0077      0.0042   0.0034   0.0029
  174                              0.0031      0.0043   0.0034   0.0035
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![High expression of the *E2F3* gene in melanoma and its influence on prognosis.\
**Notes:** (**A**) A "Mutation Matrix" plot between genes and samples of melanoma tissue that contains 20 top ranked genes (rows) and TCGA samples (columns) with each box representing a Gene-Sample combination. The *E2F3* gene ranked as the top melanoma-related gene. (**B**) E2F3 has been studied in many tissues, including eye, lung, and breast, but studies of the skin are extremely rare. (**C**) The overexpression percentage (%) is represented as a histogram across different primary tissue types, and the overexpression percentage of the *E2F3* gene in melanoma is the highest. (**D**) The *E2F3* gene shows an increased expression level in melanoma tissues compared with normal tissues. The left was derived from the TCGA database, and the right was from the GSE3189 (more details can be found at <https://www.oncomine.org/>). (**E**) The ROC curve of GSE3189. (**F**) The overexpression of the *E2F3* gene affected the OS of 454 melanoma patients. (**G**) The overexpression of the *E2F3* gene affected the DFS (disease free since initial treatment) of 398 melanoma patients.\
**Abbreviations:** CNV, copy number variation; DFS, disease-free survival; NRD, no related data; OS, overall survival; SKCM, skin cutaneous melanoma; TCGA, The Cancer Genome Atlas.](ott-11-5303Fig1){#f1-ott-11-5303}

![Copy number variation results in the high expression of the *E2F3* gene and affects prognosis.\
**Notes:** (**A**) COSMIC shows that E2F3 variations in solid cancer are dominated by CNV gains and overexpression. (**B**) The *E2F3* gene shows an increased expression level in patients with high E2F3 copy number (unpaired *t*-test, \**P*\<0.0001). (**C**) The expression of the *E2F3* gene is significantly positively correlated with the CNV level. (**D**) The copy number of the *E2F3* gene affects the OS of 357 melanoma patients. (**E**) The copy number of the *E2F3* gene affects the DFS of 315 melanoma patients.\
**Abbreviations:** CNV, copy number variation; COSMIC, catalog of cancer somatic mutations; DFS, disease-free survival; OS, overall survival.](ott-11-5303Fig2){#f2-ott-11-5303}

![DNA methylation does not result in the high expression of the *E2F3* gene or affect prognosis.\
**Notes:** (**A**) The *E2F3* gene shows an increased expression level in patients with hypomethylation. (**B**) The expression of the *E2F3* gene is significantly inversely correlated with the methylation level. (**C** and **D**) The methylation of the *E2F3* gene does not affect OS and DFS. (**E**) The promoter region of E2F3 is enriched with CpG islands (more details can be found in MethPrimer at <http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi>). The BSP1 synthesis sequence F1R1 contains 19 CG sites. (**F**) Methylation of 19 CG sites in four cell lines. (**G**) Relative expression by PCR. (**H**) Methylation levels in cells. (**I**) Methylation and expression levels are inconsistent in the four cell lines.\
**Abbreviations:** DFS, disease-free survival; OS, overall survival.](ott-11-5303Fig3){#f3-ott-11-5303}

![Carcinogenic properties of the *E2F3* gene.\
**Notes:** (**A**) Colony formation of the cells after transient transfection with E2F3-shRNA or NC-shRNA. (**B**) Histogram showing colony formation in the groups. (**C**) Images of anchorage-dependent growth. (**D**) The average number of colonies decreased following *E2F3* gene knockdown. (**E**) The *E2F3* gene affects cell proliferation. Proliferation was assessed using an EdU cell proliferation assay kit (magnification, 100×). (**F**) The cell proliferation rate decreased following *E2F3* gene knockdown. (**G**) The cell cycle distribution in melanoma cells transfected with E2F3-shRNA or NC-shRNA. (**H**) Histogram showing the cell cycle distribution (%). All the results are shown as the mean ± SEM, \**P*\<0.05.\
**Abbreviations:** KD, knockdown; NC, negative control.](ott-11-5303Fig4){#f4-ott-11-5303}
